文献速递免疫规划传染病防控与疫情报告

荷兰全国性研究:调整暴露机会后新冠疫苗对SARS-CoV-2感染的保护效果(Delta时期,2021年7月至12月)

COVID-19 vaccine effectiveness against SARS-CoV-2 infection during the Delta period, a nationwide study adjusting for chance of exposure, the Netherlands, July to December 2021.
PubMed 文献 · Euro Surveill · 2022-01-01

本研究在荷兰开展检测阴性病例对照研究,纳入2021年7月4日至12月8日Delta变异株流行期间在社区检测点检测的成人,评估全程接种mRNA或载体疫苗对SARS-CoV-2感染的保护效果,并检验暴露混杂。调整暴露机会后疫苗保护效果为64%(95%CI:50-73),较未调整模型仅略低,提示常规数据可准确估计疫苗保护效果。

要点

  • 调整暴露机会后全程接种对SARS-CoV-2感染的保护效果为64%(95%CI:50-73)。
  • ≥50岁人群mRNA疫苗保护效果从接种后<120天的81%降至≥120天的61%(p=0.01)。
  • 暴露机会未对疫苗保护效果估计造成重大混杂。

核心结论

  • SARS-CoV-2暴露机会未对COVID-19疫苗针对感染的保护效果估计造成重大混杂,提示使用常规收集数据无需暴露信息即可准确估计疫苗保护效果。

研究设计与样本

  • 检测阴性病例对照研究,纳入2021年7月4日至12月8日Delta变异株流行期间在社区设施检测SARS-CoV-2的成人。

主要发现

  • 模型3调整暴露机会后全程接种对感染的保护效果为64%(95%CI:50-73),模型1为68%(95%CI:58-76),模型2为67%(95%CI:56-75)。
  • ≥50岁人群mRNA疫苗保护效果(模型3)从接种后<120天的81%(95%CI:66-91)显著下降至≥120天的61%(95%CI:22-80)(p=0.01)。
  • 模型1中≥50岁人群mRNA疫苗保护效果从83%降至59%,模型2中从81%降至56%。

关键数值与推荐

  • 模型1调整年龄、性别和日历周;模型2额外调整合并症和教育水平;模型3额外调整SARS-CoV-2暴露(密切接触者数量、到访繁忙地点、家庭规模、佩戴口罩、接触SARS-CoV-2病例)。
  • 按年龄、疫苗类型和接种后时间分层分析。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BackgroundDifferential SARS-CoV-2 exposure between vaccinated and unvaccinated individuals may confound vaccine effectiveness (VE) estimates.AimWe conducted a test-negative case-control study to determine VE against SARS-CoV-2 infection and the presence of confounding by SARS-CoV-2 exposure.MethodsWe included adults tested for SARS-CoV-2 at community facilities between 4 July and 8 December 2021 (circulation period of the Delta variant). The VE against SARS-CoV-2 infection after primary vaccination with an mRNA (Comirnaty or Spikevax) or vector-based vaccine (Vaxzevria or Janssen) was calculated using logistic regression adjusting for age, sex and calendar week (Model 1). We additionally adjusted for comorbidity and education level (Model 2) and SARS-CoV-2 exposure (number of close contacts, visiting busy locations, household size, face mask wearing, contact with SARS-CoV-2 case; Model 3). We stratified by age, vaccine type and time since vaccination.ResultsVE against infection (Model 3) was 64% (95% CI: 50-73), only slightly lower than in Models 1 (68%; 95% CI: 58-76) and 2 (67%; 95% CI: 56-75). Estimates stratified by age group, vaccine and time since vaccination remained similar: mRNA VE (Model 3) among people ≥ 50 years decreased significantly (p = 0.01) from 81% (95% CI: 66-91) at < 120 days to 61% (95% CI: 22-80) at ≥ 120 days after vaccination. It decreased from 83% to 59% in Model 1 and from 81% to 56% in Model 2.ConclusionSARS-CoV-2 exposure did not majorly confound the estimated COVID-19 VE against infection, suggesting that VE can be estimated accurately using routinely collected data without exposure information.

来源:Euro Surveill,查看原文。版权归原作者所有。

引用

  1. van Ewijk CE, Kooijman MN, Fanoy E, et al. COVID-19 vaccine effectiveness against SARS-CoV-2 infection during the Delta period, a nationwide study adjusting for chance of exposure, the Netherlands, July to December 2021. Euro Surveill. 2022. PMID: 36367011. doi:10.2807/1560-7917.ES.2022.27.45.2200217

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。